# STEEL Percutaneous Coronary Intervention

Study · id `cardio:ct-nct02327624` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02327624](<https://clinicaltrials.gov/study/NCT02327624>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02327624

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT02327624. Randomized; no masking; primary purpose treatment. Start 2015-06 (actual); primary completion 2018-05-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT02327624, source copy `cardio:ctgov-nct02327624-2019-01-23`, retrieved 2026-10-26)
- Started: 2015-06 (actual) (ClinicalTrials.gov record NCT02327624, source copy `cardio:ctgov-nct02327624-2019-01-23`, retrieved 2026-10-26)
- Primary completion: 2018-05-31 (actual) (ClinicalTrials.gov record NCT02327624, source copy `cardio:ctgov-nct02327624-2019-01-23`, retrieved 2026-10-26)
- Completion: 2018-05-31 (actual) (ClinicalTrials.gov record NCT02327624, source copy `cardio:ctgov-nct02327624-2019-01-23`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02327624, source copy `cardio:ctgov-nct02327624-2019-01-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02327624-2019-01-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: STEEL Percutaneous Coronary Intervention
- Acronym: STEEL-PCI
- Condition: Coronary Artery Disease
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Ticagrelor 60
- Intervention (Drug): Ticagrelor 90
- Lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust (`cardio:org-sheffield-teaching-hospitals-nhs-foundation-trust`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: d351631c1898e27bd498de1c85cc04b0e175f2d4d88fbac0d69f459a95ff4141
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
